RxDoctor Payments Data

Jennifer Elumelu, OD

Optometrist · New Orleans, LANPI 1043733033

Payments from drug & device makers

$3,113in general payments, 2019–2025

Across 106 payments — averaging $29.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$855
  • Bausch & Lomb Americas Inc.$451
  • Glaukos Corporation$359
  • Shire North American Group Inc$187
  • Biotissue Holdings Inc.$164
  • AbbVie$154
  • plus $942 from 11 others

What the payments were for

  • Food & beverage$3,113100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,113 in reported general payments places this provider in the 75th percentile of 500 optometrist providers in Louisiana.

See all optometrist providers in Louisiana

Medicare billing

Part B allowed, 2024
$23,779
Medicare patients
142
Services billed
273

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine28$16,452
XiidraLifitegrast12$8,239
CombiganBrimonidine Tartrate/Timolol18$4,597
LumiganBimatoprost12$4,150
Fluorometholone14$952
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha37$522
MoxifloxacinMoxifloxacin Hcl23$460
ErythromycinErythromycin Base25$293
Timolol Maleate16$212
Latanoprost23$102
Doxycycline Hyclate11$73
Cephalexin17$50

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Combigan, Lumigan$154$25,19958 claims
Bausch & Lomb Americas Inc.Xiidra$451$8,23912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 500 optometrist providers in Louisiana.

Other optometrist in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →